Cart (0 Items)
Your cart is currently empty.
View ProductsReslizumab Biosimilar – Anti-IL5 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Reslizumab Biosimilar - Anti-IL5 mAb - Research Grade |
|---|---|
| Source | CAS 241473-69-8 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | Reslizumab,CDP-835,JES1-39D10,SCH55700,IL5,anti-IL5 |
| Reference | PX-TA1198 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG4-nd |
| Clonality | Monoclonal Antibody |
Description of Reslizumab Biosimilar - Anti-IL5 mAb - Research Grade
General information on Anti-IL5(Homo sapiens) (Reslizumab) Monoclonal Antibody
Reslizumab is a humanized interleukin 5 (IL-5) antagonist monoclonal antibody (IgG4 kappa), produced by recombinant DNA technology in murine non-secretory myeloma 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophil markers. Elevated levels of eosinophils increase the risk of exacerbation of asthma, including allergic and non-allergic forms of asthma characterized by eosinophilia. By targeting IL-5 and disrupting its signaling pathway, reslizumab aims to inhibit the maturation of eosinophils and promote programmed cell death. Reslizumab is sold as Cinqaero in Europe.
Related products
Antigen
Interleukin-5(IL5)
PX-P4859 210€
Antigen
IL5RA recombinant protein
PX-P5204 385€
Antigen
CD125 / IL5RA, C-His, recombinant protein
PX-P5556 385€
Antigen
Mouse IL5, N-His, recombinant protein
PX-P5988 385€
SIL
Reviews
Il n’y a pas encore d’avis.